Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-tolerated Tolerability profile observed suggests doses investigated were at the lower end of the therapeutic range Much higher doses of dapiglutide are being investigated in the ongoing 13-week Phas ...

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK, May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs. "OZEM ...

Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to ...

Nestle is launching a new frozen-food brand, Vital Pursuit, aimed at the growing market of consumers who are using GLP-1 drugs like Ozempic and Wegovy. Over the last year, the buzzy weight loss and diabetes drugs have taken off as more options hit the market and celebrities like Oprah Winfrey and Elon Musk endorse them. Roughly one in eight adults in the U.S. has used a GLP-1 drug at some point, according to a recent survey from health policy research organization KFF. Roughly half of those Americans, or ar ...

About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical wri ...

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — the class of drugs like Ozempic and Wegovy that have skyrocketed in popularity — were not previously offered as part of that program. Customers can access the compounded GLP-1 medic ...

Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for profound, durable, and broad metabolic benefit that can be achieved from single-admi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32593 Global Partners LP (Exact name of registrant as specified in its charter) Delaware 74-3140887 (State or ot ...

财务数据和关键指标变化 - 第一季度调整后EBITDA为5,600万美元,较2023年同期的7,600万美元下降26.3% [18] - 第一季度净亏损560万美元,而2023年同期净利润2,900万美元 [18] - 第一季度可分配现金流为1,580万美元,较2023年同期的4,630万美元下降65.9% [19] - 第一季度调整后可分配现金流为1,600万美元,较2023年同期的4,630万美元下降65.5% [19] - 截至3月31日,过去12个月的分配覆盖率为1.6倍,考虑优先股分配后为1.5倍 [19] 各条业务线数据和关键指标变化 GDSO业务 - 产品毛利增加420万美元至1.877亿美元 [20] - 汽油分销产品毛利增加80万美元至1.216亿美元,主要反映燃料毛利率同比上升 [20] - 每加仑燃料毛利率从2023年第一季度的0.32美元上升至0.33美元 [21] - 站点运营产品毛利增加340万美元至6,610万美元,公司在门店表现出色 [23] - 截至季末,公司拥有1,601个站点,另有64个站点通过Spring Partners零售合资经营 [24] 批发业务 - 产品毛利减少370万美元至4,940万美元 [25] - 汽油和汽油混合物产品毛利增加930万美元至2,970万美元,主要由于收购Motiva终端 [25] - 柴油和其他油品产品毛利减少1,300万美元至1,970万美元,主要由于残余油市场状况欠佳 [26] 商业业务 - 产品毛利减少110万美元至700万美元,主要由于市场状况欠佳 [27] 各个市场数据和关键指标变化 - 收购了4个位于马萨诸塞州、康涅狄格州和新泽西州的Linden、Woodbury和新罕布什尔终端,使公司的终端网络和总储能能力从990万桶增加到2,130万桶 [8][9][10][11] - 收购了Motiva的25个液体能源终端,这些优质资产有25年的take-or-pay承诺,公司正在优化这些设施以提高投资、扩张和运营效率 [13] 公司战略和发展方向及行业竞争 - 公司正在寻求收购机会,但没有稳定的收购渠道,会根据资产是否符合公司最佳利益来选择 [55] - 公司正在寻求在休斯顿市场进一步扩张,并希望能够利用新收购的终端资产来支持这一目标 [52][53] - 公司正在努力提高新收购终端的业务量,并寻求投资机会来优化这些设施 [43][44][45][48] 管理层对经营环境和未来前景的评论 - 管理层对新收购的终端资产感到非常高兴,认为这些资产地理位置和运营情况都非常适合公司,将增强公司的盈利能力 [8][13] - 管理层认为,随着公司继续优化新收购的终端资产,未来有望超出原有预期 [47][48] - 管理层对公司的财务状况和现金流覆盖能力表示满意,认为这将为未来的分红增长提供支持 [57][58]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners LP Reports First-Quarter 2024 Financial Results Waltham, Mass., May 8, 2024 – Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the first quarter ended March 31, 2024. CEO Commentary Eric Slifka, the Partnership’s President and Chief Executive ...